Development of an Nrf2 inhibitor for the treatment of Nrf2-addicted cancer
Description: Mutations in the Keap1-Nrf2 pathway are common events in human cancers, however there are currently no specific treatment options for tumors with activated Nrf2 signaling. Therefore, the purpose of this research is to identify compounds which function to specifically kill Nrf2-dependent tumors.
Amount: ¥4,290,000
Funding type: fellowship
Funder scheme: Grant-in-Aid for Early-Career Scientists
Start date: 2019-04-01
End date: 2021-03-31
Investigator: Liam Baird
Institution: Tohoku University
Funded outputs count: 8
Funder award ID: 19K16512
OpenAlex ID: G4690036629